Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The treatment of postmenopausal women with advanced breast cancer with buserelin

Summary

Repeated administration of long-acting analogues of gonadotrophin-releasing hormone down-regulates the pituitary gonadotrophins and gonadal hormones. The activity of these compounds in premenopausal women with breast cancer has been previously noted. In an attempt to cause a highly selective medical hypophysectomy 18 consecutive postmenopausal women with symptomatic advanced breast cancer were treated with intranasal buserelin in divided dosages of either 600 or 1000 μg daily. The pituitary gonadotrophins were suppressed in all patients, without objective evidence of response. This is in contrast with an earlier finding that the long-acting analogues of gonadotrophin-releasing hormone were effective in postmenopausal patients with breast cancer.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bates T, Rubens RD, Bulbrook RD et al (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782

  2. 2.

    Beatson GT (1896a) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107

  3. 3.

    Beatson GT (1896b) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet II:162–165

  4. 4.

    Fattah DI, Chard T (1981) Method for measuring sex hormone binding globulin. Clin Chem 27:1277–1279

  5. 5.

    Harvey HA, Lipton A, Santen RJ et al. (1981) Phase II study of a gonadotropin releasing hormone analogue in postmenopausal advanced breast cancer. Proc Am Soc Clin Oncol C436

  6. 6.

    Klijn JGM, De Jong FH (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1:1213–1216

  7. 7.

    La Rossa JT, Strong MS, Melby JC (1978) Endocrinologically incomplete transphenoidal hypophysectomies with relief of bone pain in breast cancer. N Engl J Med 298:1332–1335

  8. 8.

    Manni A, Pearson OH, Brodkey J, Marshall JS (1979) Transphenoidal hypophysectomy in breast cancer. Cancer, 44: 2330–2337

  9. 9.

    McMillin JM, Seal US, Theologides A (1977) Prolactin dynamics following transphenoidal hypophysectomy for metastatic carcinoma of the breast. Cancer 39:2254–2257

  10. 10.

    Nillius S-J, Bergquist C, Wide L (1978) Inhibition of ovulation, in women by chronic treatment with a stimulatory LRH analogue — a new approach to birth control? Contraception 17:537–545

  11. 11.

    Schinzinger (1889) Über Carcinoma Mammae (abst) Zbl Chir 16:55

  12. 12.

    Wang DY, Bulbrook RD, Rubens RD et al. (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782

Download references

Author information

Correspondence to T. A. Lister.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Waxman, J.H., Harland, S.J., Coombes, R.C. et al. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother. Pharmacol. 15, 171–173 (1985). https://doi.org/10.1007/BF00257531

Download citation

Keywords

  • Breast Cancer
  • Cancer Research
  • Postmenopausal Woman
  • Premenopausal Woman
  • Advanced Breast